Octreotide Side Effects: What Studies Report

Octreotide is a synthetic octapeptide analogue of somatostatin used as a prescription medicine in several regions. Because it binds somatostatin receptors expressed across the gut, pancreas, pituitary and vasculature, the adverse events described in the published literature tend to cluster in those same systems. This page collects what trials, reviews and safety studies reported about those events, and where the record is thin.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or treatment decision. Nothing here describes how a product is prepared, administered or scheduled.

Evidence tier and how to read this page

Evidence tier: Established. Octreotide has approved immediate-release and long-acting formulations, an approved oral capsule formulation in some markets, randomised phase 3 data, and decades of post-approval use. That means the safety record rests on regulatory prescribing information plus controlled trials and observational studies, rather than on isolated preclinical work. Even so, adverse-event frequencies differ sharply between indications — acromegaly, neuroendocrine tumours, congenital hyperinsulinism and off-label uses such as chylothorax are not interchangeable populations.

Approved-product labelling is the single most complete list of recognised adverse reactions for any licensed octreotide product, and prescribing information for approved octreotide products lists gastrointestinal reactions, gallbladder abnormalities, changes in glucose regulation, bradycardia, injection-site reactions and thyroid-function changes among recognised effects. Individual studies below add texture to specific items on that list.

Gastrointestinal Effects: What Studies Report

Gastrointestinal complaints dominate the tolerability discussion in nearly every octreotide indication, which is unsurprising for a drug that suppresses gut hormone secretion and motility. A review of octreotide in acromegaly surveyed the efficacy and tolerability of the drug in that setting, including the gastrointestinal complaints that shaped long-term adherence (https://pubmed.ncbi.nlm.nih.gov/30754185/). In a 2022 report of durable biochemical response and safety with oral octreotide capsules in acromegaly, researchers reported on tolerability over extended treatment in patients maintained on the oral formulation (https://pubmed.ncbi.nlm.nih.gov/36173649/).

Long-term oncology exposure has also been characterised. A prospective study of long-term octreotide treatment in patients with progressive metastatic gastrinoma assessed antitumour efficacy during sustained therapy and documented the treatment experience of that cohort (https://pubmed.ncbi.nlm.nih.gov/11900219/). Studies of this kind matter for side-effect intent because they describe what happened over months to years, not only during a short titration window.

Gallbladder and Biliary Findings: What Studies Report

Suppression of gallbladder contractility is a well-recognised consequence of somatostatin-analogue pharmacology, and gallstones, biliary sludge and cholecystitis appear in approved prescribing information for octreotide products as recognised adverse reactions. The clinical literature on long-term somatostatin-analogue therapy in acromegaly has examined how tolerability, including biliary monitoring, influenced long-term management (https://pubmed.ncbi.nlm.nih.gov/30754185/). Biliary findings are frequently asymptomatic and detected on imaging rather than reported as symptoms, which is one reason prevalence estimates vary between cohorts.

Blood Glucose and Endocrine Findings: What Studies Report

Because octreotide suppresses insulin, glucagon and growth hormone, glucose regulation can move in either direction. That property is exploited therapeutically in hyperinsulinism: researchers evaluated the efficacy and safety of octreotide treatment for diazoxide-unresponsive congenital hyperinsulinism in a Chinese cohort and reported both treatment response and adverse events in those children (https://pubmed.ncbi.nlm.nih.gov/32851339/). In acromegaly, where growth-hormone suppression is the goal, glucose changes are instead monitored as a potential adverse effect, and reviews of octreotide in acromegaly have discussed the metabolic consequences of sustained somatostatin-receptor agonism (https://pubmed.ncbi.nlm.nih.gov/30754185/). Approved labelling also lists thyroid-function abnormalities and vitamin B12 changes among recognised effects with long-term use.

Hematologic Reports: What Studies Report

Rare events are usually captured as case reports and pharmacovigilance summaries rather than in trials. A 2017 report in Pharmacotherapy described octreotide-associated neutropenia, drawing attention to a haematologic signal that does not feature prominently in the common-adverse-event tables (https://pubmed.ncbi.nlm.nih.gov/28488730/). Reports like this illustrate a general limitation: uncommon effects are identified after approval, and their true incidence is often unknown because the denominator of treated patients is not measurable from case literature alone.

Long-Term Trial Safety: What Studies Report

The most informative controlled safety dataset in neuroendocrine tumours comes from NETTER-1. The final overall survival and long-term safety analysis of that open-label, randomised, controlled phase 3 trial compared ¹⁷⁷Lu-Dotatate plus long-acting octreotide with high-dose long-acting octreotide (60 mg every 4 weeks) in patients with midgut neuroendocrine tumours, and the investigators reported long-term safety outcomes alongside survival (https://pubmed.ncbi.nlm.nih.gov/34793718/). Because the comparator arm received high-dose long-acting octreotide, the trial is one of the few settings in which extended high-dose exposure was followed prospectively with systematic adverse-event collection (https://pubmed.ncbi.nlm.nih.gov/34793718/).

For acromegaly, the oral capsule literature added a different kind of long-term signal: researchers reported durable biochemical response and safety data in patients treated with oral octreotide capsules, allowing comparison of an oral route with injectable somatostatin analogues (https://pubmed.ncbi.nlm.nih.gov/36173649/).

Injection- and Formulation-Related Findings: What Studies Report

Route of administration shapes the side-effect experience. Injection-site pain, nodules and discomfort are listed in approved prescribing information for injectable octreotide products, and a 2022 comparison between somatostatin analogue injections examined differences in the injection experience across products (https://pubmed.ncbi.nlm.nih.gov/35649076/). The availability of an oral formulation changed that calculus for some patients with acromegaly, and the study of oral octreotide capsules reported on safety in patients maintained on that formulation rather than on repeated injections (https://pubmed.ncbi.nlm.nih.gov/36173649/).

Infants and Children: What Studies Report

Paediatric safety has been examined separately because neonates and infants are not physiologically comparable to adults. A pharmacoepidemiology and drug safety analysis investigated octreotide use and safety in infants with hyperinsulinism, describing patterns of use and the adverse events recorded in that population (https://pubmed.ncbi.nlm.nih.gov/27910218/). The Chinese cohort study of diazoxide-unresponsive congenital hyperinsulinism similarly reported efficacy and safety findings in treated children (https://pubmed.ncbi.nlm.nih.gov/32851339/). Clinicians treating infants weigh these specific datasets rather than extrapolating from adult acromegaly or oncology trials.

Off-Label Settings: What Studies Report

Octreotide has been studied in several conditions outside its licensed indications, and the safety evidence in those settings is correspondingly smaller. A review in Current Opinion in Pulmonary Medicine discussed octreotide and chylothorax, summarising the reported clinical experience with the drug in that context (https://pubmed.ncbi.nlm.nih.gov/16825878/). A treatment-options review of primary intestinal lymphangiectasia likewise placed octreotide among the approaches described for that rare disorder (https://pubmed.ncbi.nlm.nih.gov/14723832/). In both cases the evidence base consists largely of case series, so adverse-event rates cannot be estimated with confidence.

Mechanistic and imaging work provides context for why effects appear where they do: a 2019 review of octreotide conjugates for tumour targeting and imaging described how the peptide's somatostatin-receptor affinity has been used to direct payloads to receptor-expressing tissue (https://pubmed.ncbi.nlm.nih.gov/31067748/). Receptor distribution beyond the intended target is the usual explanation offered for systemic effects.

Animal Data: What Studies Report

Veterinary literature occasionally reports on octreotide separately from human medicine. A retrospective study of 18 dogs examined the use of octreotide for protein-losing enteropathy and reported the outcomes and tolerability observed in those cases (https://pubmed.ncbi.nlm.nih.gov/38038236/). Animal findings do not transfer to people, and they are included here only to show the breadth of the published record.

How the reported findings group together

Limitations of the published safety record

• Indication-specific populations. The patients studied in NETTER-1 differ from those in acromegaly or paediatric hyperinsulinism cohorts, so adverse-event profiles are not directly comparable across those reports (https://pubmed.ncbi.nlm.nih.gov/34793718/).
• Rare events emerge late. Signals such as octreotide-associated neutropenia surfaced in post-approval reporting rather than in randomised trials (https://pubmed.ncbi.nlm.nih.gov/28488730/).
• Small off-label series. Reviews of chylothorax relied on limited published experience rather than controlled comparisons (https://pubmed.ncbi.nlm.nih.gov/16825878/).
• Formulation matters. Immediate-release, long-acting and oral products were studied separately, and the oral capsule safety data come from their own trial programme (https://pubmed.ncbi.nlm.nih.gov/36173649/).

Trademarks and affiliation

Brand names for octreotide products, including the injectable and oral capsule brands marketed in various countries, are the property of their respective holders; each such brand name is a trademark of its owner. PeptideU is an independent educational resource and is not affiliated with or endorsed by any manufacturer, distributor, trademark holder or regulatory agency. Octreotide is a prescription medicine in the jurisdictions where it is approved, and availability, labelling and approved indications differ by country.

For a structured walkthrough of octreotide pharmacology, receptor subtypes, formulations and the indications in which it has been studied, the companion course material covers the background that this safety-focused page does not repeat.

References

• Octreotide-Associated Neutropenia (Pharmacotherapy, 2017)
• 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results (The Lancet Oncology, 2021)
• Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma (Cancer, 2002)
• Octreotide and chylothorax (Current Opinion in Pulmonary Medicine, 2006)
• Octreotide for acromegaly (Expert Review of Endocrinology & Metabolism, 2007)
• Octreotide Conjugates for Tumor Targeting and Imaging (Pharmaceutics, 2019)
• Comparison between somatostatin analog injections (Revista da Associação Médica Brasileira, 2022)
• Efficacy and safety of octreotide treatment for diazoxide-unresponsive congenital hyperinsulinism in China (Pediatric Investigation, 2020)
• Octreotide use and safety in infants with hyperinsulinism (Pharmacoepidemiology and Drug Safety, 2017)
• Primary Intestinal Lymphangiectasia (Current Treatment Options in Gastroenterology, 2004)
• Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases (Journal of Veterinary Internal Medicine, 2024)
• Durable biochemical response and safety with oral octreotide capsules in acromegaly (European Journal of Endocrinology, 2022)